Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acquired chemotherapy resistance in ovarian cancer.

Literature DB >> 29232469

Acquired chemotherapy resistance in ovarian cancer.

Abstract

Most women diagnosed with high-grade serous ovarian cancer (HGSC) develop recurrent disease and chemotherapy resistance, despite initially responding to treatment. The genomic characteristics of HGSC samples collected at initial surgery have been extensively studied. However, due to challenges of sample collection following treatment, much less is known about the molecular features of recurrent disease. Our recent studies have identified mechanisms of acquired resistance and biomarkers in recurrent HGSCs that could lead to improved treatment approaches.

Entities: Disease Species

Keywords: ctDNA; heterogeneity; ovarian cancer; platinum-resistant; relapse

Mesh：

Substances：
Antineoplastic Agents

Year: 2017 PMID： 29232469 DOI： 10.1093/annonc/mdx446

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

46 in total

Review 1. Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.

Authors: Zehong Yang; Hongyan Xu; Xiaojun Zhao
Journal: Adv Sci (Weinh) Date: 2020-03-20 Impact factor: 16.806

2. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

Authors: Yanxia Zhao; Jinghong Cao; Alexander Melamed; Michael Worley; Allison Gockley; Dennis Jones; Hadi T Nia; Yanling Zhang; Triantafyllos Stylianopoulos; Ashwin S Kumar; Fotios Mpekris; Meenal Datta; Yao Sun; Limeng Wu; Xing Gao; Oladapo Yeku; Marcela G Del Carmen; David R Spriggs; Rakesh K Jain; Lei Xu
Journal: Proc Natl Acad Sci U S A Date: 2019-01-18 Impact factor: 11.205

3. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.

Authors: Renaud Sabatier; Séverine Garnier; Arnaud Guille; Nadine Carbuccia; Jihane Pakradouni; José Adelaide; Magali Provansal; Maria Cappiello; Frédérique Rousseau; Max Chaffanet; Daniel Birnbaum; Emilie Mamessier; Anthony Gonçalves; François Bertucci
Journal: Front Oncol Date: 2022-07-29 Impact factor: 5.738

Acquired chemotherapy resistance in ovarian cancer.

Review 1. Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.

2. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

3. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.

4. Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.

5. Expressions and clinical significances of STAT3 and Grim19 in epithelial ovarian cancer.

6. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.

7. The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.

8. The involvement of small heat shock protein in chemoresistance in ovarian cancer - in vitro study.

9. NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway.

10. Prognostic implications of tumour-infiltrating lymphocytes for recurrence in epithelial ovarian cancer.